<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/246934</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;246934v2</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;246934</article-id><article-id pub-id-type="other" hwp:sub-type="slug">246934</article-id><article-id pub-id-type="other" hwp:sub-type="tag">246934</article-id><article-version>1.2</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Genetics" hwp:journal="biorxiv"><subject>Genetics</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Inherited <italic toggle="yes">BRCA1</italic> epimutation as a novel cause of breast and ovarian cancer</article-title></title-group><author-notes hwp:id="author-notes-1"><fn id="n1" fn-type="equal" hwp:id="fn-1" hwp:rev-id="xref-fn-1-1 xref-fn-1-2 xref-fn-1-3 xref-fn-1-4"><label>*</label><p hwp:id="p-1">These authors contributed equally to the manuscript.</p></fn><corresp id="cor1" hwp:id="corresp-1"><bold>Corresponding author and address for correspondence:</bold> Professor DGR Evans, Manchester Centre for Genomic Medicine, St. Mary’s Hospital, Oxford Road Manchester, M13 9WL, UK. Tel: 44 (0)161 276 6206, Fax: 44 (0)161 276 6145, Email: <email hwp:id="email-1">gareth.evans@mft.nhs.uk</email></corresp></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" corresp="yes" hwp:id="contrib-1"><name name-style="western" hwp:sortable="Evans D. Gareth R."><surname>Evans</surname><given-names>D. Gareth R.</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-1" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-2"><name name-style="western" hwp:sortable="van Veen Elke M."><surname>van Veen</surname><given-names>Elke M.</given-names></name><degrees>M.Sc.</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-2" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Byers Helen J."><surname>Byers</surname><given-names>Helen J.</given-names></name><degrees>B.Sc.</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-2" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Wallace Andrew J."><surname>Wallace</surname><given-names>Andrew J.</given-names></name><degrees>Ph.D.</degrees><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-3" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Ellingford Jamie M."><surname>Ellingford</surname><given-names>Jamie M.</given-names></name><degrees>Ph.D.</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-4" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Beaman Glenda"><surname>Beaman</surname><given-names>Glenda</given-names></name><degrees>Ph.D.</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-5" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-5" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Santoyo-Lopez Javier"><surname>Santoyo-Lopez</surname><given-names>Javier</given-names></name><degrees>Ph.D.</degrees><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Aitman Timothy J."><surname>Aitman</surname><given-names>Timothy J.</given-names></name><degrees>D.Phil.</degrees><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-2" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" hwp:id="contrib-9"><name name-style="western" hwp:sortable="Eccles Diana M."><surname>Eccles</surname><given-names>Diana M.</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="a7" hwp:id="xref-aff-7-1" hwp:rel-id="aff-7">7</xref></contrib><contrib contrib-type="author" hwp:id="contrib-10"><name name-style="western" hwp:sortable="Lalloo Fiona I."><surname>Lalloo</surname><given-names>Fiona I.</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-6" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-11"><name name-style="western" hwp:sortable="Smith Miriam J."><surname>Smith</surname><given-names>Miriam J.</given-names></name><degrees>Ph.D.</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-6" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-7" hwp:rel-id="aff-5">5</xref><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-3" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-12"><name name-style="western" hwp:sortable="Newman William G."><surname>Newman</surname><given-names>William G.</given-names></name><degrees>Ph.D.</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-7" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-2" hwp:rel-id="aff-4">4</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-8" hwp:rel-id="aff-5">5</xref><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-4" hwp:rel-id="fn-1">*</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4 xref-aff-1-5 xref-aff-1-6 xref-aff-1-7"><label>1</label><institution hwp:id="institution-1">Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre</institution>, Manchester, M13 9PL, <country>UK</country>.</aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1"><label>2</label><institution hwp:id="institution-2">Prevention Breast Cancer Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester</institution>, Manchester, M23 9LT, <country>UK</country>.</aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1"><label>3</label><institution hwp:id="institution-3">The Christie NHS Foundation Trust</institution>, Manchester, M20 4BX, <country>UK</country>.</aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1 xref-aff-4-2"><label>4</label><institution hwp:id="institution-4">Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester</institution>, M20 4BX, Manchester, <country>UK</country>.</aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1 xref-aff-5-2 xref-aff-5-3 xref-aff-5-4 xref-aff-5-5 xref-aff-5-6 xref-aff-5-7 xref-aff-5-8"><label>5</label><institution hwp:id="institution-5">Manchester Centre for Genomic Medicine, St. Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre</institution>, Manchester, M13 9WL, <country>UK</country>.</aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1 xref-aff-6-2"><label>6</label><institution hwp:id="institution-6">Centre for Genomic and Experimental Medicine, and Edinburgh Genomics, University of Edinburgh</institution>, Edinburgh, EH4 2XU, <country>UK</country></aff><aff id="a7" hwp:id="aff-7" hwp:rev-id="xref-aff-7-1"><label>7</label><institution hwp:id="institution-7">Cancer Sciences Academic Unit and Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton and University Hospital Southampton Foundation Trust</institution>, Southampton, <country>UK</country>.</aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2018-01-15T06:51:27-08:00">
    <day>15</day><month>1</month><year>2018</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-01-18T15:09:14-08:00">
    <day>18</day><month>1</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2018-01-15T06:56:51-08:00">
    <day>15</day><month>1</month><year>2018</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-01-18T15:15:08-08:00">
    <day>18</day><month>1</month><year>2018</year>
  </pub-date><elocation-id>246934</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2018-01-15"><day>15</day><month>1</month><year>2018</year></date>
<date date-type="rev-recd" hwp:start="2018-01-18"><day>18</day><month>1</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-01-18"><day>18</day><month>1</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="license-1"><p hwp:id="p-2">This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></license></permissions><self-uri xlink:href="246934.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/246934v2.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="246934.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/246934v2/246934v2.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/246934v2/246934v2.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><sec hwp:id="sec-1"><title hwp:id="title-2">Background</title><p hwp:id="p-3">Pathogenic variants in <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> are identified in ~20% of families with multiple individuals with early-onset breast/ovarian cancer. Extensive searches for additional highly penetrant genes or alternative mutational mechanisms altering <italic toggle="yes">BRCA1/2</italic> have not explained the missing heritability. For the first time, we report transgenerational epigenetic silencing of <italic toggle="yes">BRCA1</italic> due to promoter hypermethylation in two families with breast/ovarian cancer.</p></sec><sec hwp:id="sec-2"><title hwp:id="title-3">Methods</title><p hwp:id="p-4"><italic toggle="yes">BRCA1</italic> promoter methylation of ten CpG dinucleotides in breast/ovarian cancer families without germline <italic toggle="yes">BRCA1/2</italic> pathogenic variants was assessed by pyrosequencing and clonal bisulfite sequencing. RNA and DNA sequencing of <italic toggle="yes">BRCA1</italic> from lymphocytes was undertaken to establish allelic expression and the presence of germline variants.</p></sec><sec hwp:id="sec-3"><title hwp:id="title-4">Findings</title><p hwp:id="p-5"><italic toggle="yes">BRCA1</italic> promoter hypermethylation was identified in two of 49 families with multiple women affected with grade 3 breast/high grade serous ovarian cancer. Soma-wide <italic toggle="yes">BRCA1</italic> promoter hypermethylation was confirmed in blood, buccal mucosa and hair follicles. Methylation levels were ~50%, consistent with the silencing of one allele and confirmed by clonal bisulfite sequencing. RNA sequencing revealed allelic loss of <italic toggle="yes">BRCA1</italic> expression in both families and this segregated with a novel heterozygous variant c.-107A&gt;T in the <italic toggle="yes">BRCA1</italic> 5’UTR.</p></sec><sec hwp:id="sec-4"><title hwp:id="title-5">Interpretation</title><p hwp:id="p-6">Our results indicate a novel mechanism for familial breast/ovarian cancer, caused by epigenetic silencing of the <italic toggle="yes">BRCA1</italic> promoter, segregating with an <italic toggle="yes">in cis</italic> 5’UTR variant in two independent families. We propose that methylation analyses are indicated in all families affected by early onset breast/ovarian cancer without a <italic toggle="yes">BRCA1/2</italic> pathogenic variant.</p></sec><sec hwp:id="sec-5"><title hwp:id="title-6">Funding</title><p hwp:id="p-7">Funded by Prevent Breast Cancer (GA 12-006 and GA 15-002) and the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007).</p></sec></abstract><counts><page-count count="23"/></counts><custom-meta-wrap>
    <custom-meta hwp:id="custom-meta-1">
      <meta-name>has-earlier-version</meta-name>
      <meta-value>yes</meta-value>
    </custom-meta>
  </custom-meta-wrap></article-meta></front><body><sec id="s1" hwp:id="sec-6"><title hwp:id="title-7">Research in context</title><sec id="s1a" hwp:id="sec-7"><title hwp:id="title-8">Evidence before this study</title><p hwp:id="p-8">In only ~20% of families with multiple individuals with early-onset breast/ovarian cancer are pathogenic variants in <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> identified. Since the discovery of these genes, extensive searches for additional highly penetrant genes or alternative mutational mechanisms altering <italic toggle="yes">BRCA1/2</italic> have not fully explained the missing heritability.</p><p hwp:id="p-9">Epigenetic alterations have been proposed as an alternative mechanism to explain the missing heritability. This epigenetic mechanism has previously been described in familial colorectal cancer, due to inherited promoter hypermethylation of <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic>. Methylation of the <italic toggle="yes">BRCA1</italic> promoter has been described in women with breast cancer but without a strong family history, but at low levels (&lt;20%), and inheritance of promoter methylation has never previously been reported. Therefore, we investigated if inherited promoter methylation of <italic toggle="yes">BRCA1</italic> may be an alternative mechanism causing familial breast/ovarian cancer.</p></sec><sec id="s1b" hwp:id="sec-8"><title hwp:id="title-9">Added value of this study</title><p hwp:id="p-10">This is the first study that describes transgenerational promoter hypermethylation of <italic toggle="yes">BRCA1</italic>, resulting in complete transcriptional silencing of one allele. This hypermethylated allele segregates with a novel upstream variant in the 5’UTR, namely c.-107A&gt;T. This novel mechanism may explain the missing heritability in some high-risk breast/ovarian cancer families.</p></sec><sec id="s1c" hwp:id="sec-9"><title hwp:id="title-10">Implications of all the available evidence</title><p hwp:id="p-11">Current clinical genetic testing approaches do not detect epigenetic changes that may account for some cases of familial breast/ovarian cancer. Detection of pathogenic variants is important to determine optimum treatment and appropriate cancer surveillance for at risk relatives. Therefore, methylation analysis in high-risk breast/ ovarian cancer patients negative for pathogenic variants in <italic toggle="yes">BRCA1/2</italic> may be informative.</p></sec></sec><sec id="s2" hwp:id="sec-10"><title hwp:id="title-11">Introduction</title><p hwp:id="p-12">Breast cancer is the commonest form of cancer in women.<sup><xref rid="c1" ref-type="bibr" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref></sup> Germline heterozygous pathogenic variants in <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> account for 2-3% of all cases<sup><xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref></sup> and up to 15% of cases of epithelial ovarian cancer.<sup><xref rid="c3" ref-type="bibr" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref></sup> In families with multiple affected individuals with early-onset disease these percentages increase substantially, with <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> variants explaining approximately 20% of familial breast cancer and a higher proportion of familial ovarian cancer cases.<sup><xref rid="c4" ref-type="bibr" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">4</xref></sup></p><p hwp:id="p-13">Over the past twenty years, there have been exhaustive efforts to identify other breast and ovarian cancer susceptibility genes. This missing heritability has been postulated to be due to other highly penetrant genes, including <italic toggle="yes">TP53</italic>; genes of modest effect, including <italic toggle="yes">PALB2/ATM</italic>; or polygenic risks due to the combination of multiple variants each of small effect size.<sup><xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref></sup> However, no other genes have been identified that confer a high risk of both breast and ovarian cancer.</p><p hwp:id="p-14">Genetic testing by DNA sequencing and copy number analysis for pathogenic exonic variants in <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> is highly sensitive (estimated to detect over 90% of pathogenic variants)<sup><xref rid="c6" ref-type="bibr" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>,<xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref></sup> and is now offered routinely to individuals at high familial risk of breast/ovarian cancer. Previous studies by our group using RNA sequencing in high-risk families have shown that deep intronic variants in <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> do not contribute significantly to this mutational spectrum.<sup><xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-2" hwp:rel-id="ref-7">7</xref></sup> Detection of pathogenic variants is important to determine appropriate cancer surveillance for at risk relatives; to reassure relatives without the familial causative variant regarding their risk and remove the burden of unnecessary screening; and to inform treatment choice, especially for poly ADP ribose polymerase (PARP) inhibitors.<sup><xref rid="c8" ref-type="bibr" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref></sup> Gene promoter epimutations have been proposed as an alternative mechanism for the transcriptional silencing of cancer-associated genes.<sup><xref rid="c9" ref-type="bibr" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref></sup> Promoter hypermethylation has been identified associated with tumor suppressor genes, both in the germline and as a somatic (acquired) event in tumor tissue,<sup><xref rid="c9" ref-type="bibr" hwp:id="xref-ref-9-2" hwp:rel-id="ref-9">9</xref></sup> and results in transcriptional silencing.</p><p hwp:id="p-15">Promoter hypermethylation of <italic toggle="yes">BRCA1</italic> is present in the tumor tissue of approximately 10% of sporadic breast cancers,<sup><xref rid="c10" ref-type="bibr" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref></sup>,<sup><xref rid="c11" ref-type="bibr" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref></sup> in breast tumors of women with <italic toggle="yes">BRCA1</italic> germline pathogenic variants,<sup><xref rid="c12" ref-type="bibr" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref></sup> and is more common in triple-negative (estrogen receptor, progesterone receptor, and HER2) breast cancer.<sup><xref rid="c13" ref-type="bibr" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref></sup> Constitutional methylation of the <italic toggle="yes">BRCA1</italic> promoter has been reported in individuals with breast cancer,<sup><xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref></sup> but this has always been at low ‘mosaic’ levels (maximum 20%) and there has been no convincing evidence that this has been inherited from one generation to the next. In contrast, inherited promoter hypermethylation of <italic toggle="yes">MLH1</italic><sup><xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref></sup> and <italic toggle="yes">MSH2</italic><sup><xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref></sup> has been reported in familial colorectal cancer. In this study, we describe the first breast/ovarian cancer families with an inherited germline variant that results in transcriptional silencing of <italic toggle="yes">BRCA1</italic> through promoter hypermethylation (secondary epimutation). This new mutational mechanism for <italic toggle="yes">BRCA1</italic> has important implications for diagnostic testing of patients at high-risk of breast/ovarian cancer and for optimum treatment selection.<sup><xref rid="c17" ref-type="bibr" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref></sup></p></sec><sec id="s3" hwp:id="sec-11"><title hwp:id="title-12">Methods</title><sec id="s3a" hwp:id="sec-12"><title hwp:id="title-13">Patients and family members</title><p hwp:id="p-16"><italic toggle="yes">BRCA1</italic> promoter methylation screening was undertaken in lymphocyte derived DNA of 49 unrelated individuals from families affected by breast/ovarian cancer and a Manchester score &gt;34 without a germline <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">BRCA2</italic> pathogenic variant. A Manchester score calculates the likelihood of detecting a pathogenic variant in <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic>.<sup><xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-3" hwp:rel-id="ref-7">7</xref>,<xref rid="c18" ref-type="bibr" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref>,<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref></sup> In our local population 158 of 220 (71·8%) families with a Manchester score of &gt;34 have had pathogenic variants in <italic toggle="yes">BRCA1/2</italic> identified by conventional genetic testing of DNA sequencing and multiplex ligation-dependent probe analysis (MLPA).</p><p hwp:id="p-17">Blood, buccal mucosa, tumor, and hair samples were collected (where possible) from affected and unaffected family members with breast/ovarian cancer when <italic toggle="yes">BRCA1</italic> promoter methylation was detected. Cancer diagnoses were confirmed from hospital records or through the North West (England) Cancer Intelligence Service, which has data on all patients with any malignancy from 1960 onwards. DNA was extracted from blood by Chemagen (Perkin Elmer), hair using QIAamp DNA investigator kit (Qiagen), buccal mucosa on the Qiagen EZ1 system, and tumor using the Cobas® DNA Sample Preparation Kit (Roche). The study was approved by the Central Manchester Research Ethics Committee (10/H1008/24) and (11/H1003/3) and written informed consent obtained from each participant.</p></sec><sec id="s3b" hwp:id="sec-13"><title hwp:id="title-14"><italic toggle="yes">BRCA1</italic> promoter methylation assays</title><p hwp:id="p-18">Genomic DNA was bisulfite converted with EZ DNA methylation kit (Zymo Research) to distinguish between methylated and unmethylated DNA. <italic toggle="yes">BRCA1</italic> promoter methylation was determined by pyrosequencing (Qiagen) across 10 CpG dinucleotides within the <italic toggle="yes">BRCA1</italic> promoter to quantify the methylation status in DNA derived from hair follicles, buccal mucosal cells, peripheral blood lymphocytes, and tumor (eMethods).</p><p hwp:id="p-19">Clonal bisulfite sequencing on a minimum of 37 clones was performed to determine if the methylation pattern was allele specific (eMethods).</p></sec><sec id="s3c" hwp:id="sec-14"><title hwp:id="title-15">RNA and DNA analysis</title><p hwp:id="p-20">To measure <italic toggle="yes">BRCA1</italic> expression, whole blood was collected in PAXgene Blood RNA tubes (PreAnalytiX) and RNA was extracted. RNA was converted to cDNA by RT-PCR using High-Capacity RNA-to-cDNA™ Kit (Applied Biosystems). Five SNPs in <italic toggle="yes">BRCA1</italic> exon 11 (rs1799949, rs16940, rs799917, rs16941, and rs16942) were genotyped by Sanger sequencing to determine if there was a difference in allelic ratios between the RNA and DNA genotypes to determine if there was silencing of one allele (eMethods, eTable 1).</p></sec><sec id="s3d" hwp:id="sec-15"><title hwp:id="title-16">Haplotype analysis</title><p hwp:id="p-21">To determine relatedness between families identified with <italic toggle="yes">BRCA1</italic> promoter methylation, 12 <italic toggle="yes">BRCA1</italic> intragenic SNPs were genotyped by Sanger sequencing to determine ancestral haplotypes (eMethods).<sup><xref rid="c20" ref-type="bibr" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref></sup> In addition, genotyping using Affymetrix Genome-Wide SNP6.0 arrays was undertaken according to the manufacturer’s protocol. Genotypes and copy number data were generated within the Affymetrix Genotyping Console (v.4.1.3.840) via the Birdseed V2 algorithm and SNP 6.0 CN/LOH algorithm, respectively.</p></sec><sec id="s3e" hwp:id="sec-16"><title hwp:id="title-17">Whole genome sequencing</title><p hwp:id="p-22">PCR-free paired end whole genome sequencing (TruSeq DNA PCR-Free, Illumina) was undertaken on a HiSeqX platform. Reads were aligned against the human assembly GRCh38 via Burrows-Wheeler Aligner (BWA v.0.6.2) and variant calling using Genome Analysis Toolkit (3.4-0-g7e26428). Annotation was performed using v89 of the Ensembl database and compared to variation identified in the gnomAD dataset (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://gnomad.broadinstitute.org" ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org" hwp:id="ext-link-2">http://gnomad.broadinstitute.org</ext-link>)<sup><xref rid="c21" ref-type="bibr" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref></sup> (eMethods).</p></sec></sec><sec id="s4" hwp:id="sec-17"><title hwp:id="title-18">Results</title><p hwp:id="p-23">To determine if promoter hypermethylation of <italic toggle="yes">BRCA1</italic> could result in familial breast/ovarian cancer, methylation assays were undertaken. <italic toggle="yes">BRCA1</italic> promoter hypermethylation was identified in two women from a screen of 49 unrelated individuals with familial breast/ovarian cancer (and a Manchester score of &gt;34) in whom previous Sanger sequencing and MLPA of <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> coding exons had not identified a pathogenic single nucleotide or copy number variant. In individuals with a Manchester score &gt;34 there is a &gt;70% likelihood of detecting a <italic toggle="yes">BRCA1/2</italic> germline pathogenic variant.<sup><xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-4" hwp:rel-id="ref-7">7</xref>,<xref rid="c18" ref-type="bibr" hwp:id="xref-ref-18-2" hwp:rel-id="ref-18">18</xref>,<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-2" hwp:rel-id="ref-19">19</xref></sup> The promoter hypermethylation was detected in a woman (Family-1; II-4, <xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1A</xref>) with breast cancer aged 39 years, and a poorly differentiated serous ovarian cancer at 48 years with a strong family history of breast cancer (Manchester score 43) and a woman (Family 2, III-2, <xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Figure 1B</xref>) with bilateral grade 3 triple negative breast cancer at age 38 and 46 years (Manchester score 35). In the two women, pyrosequencing assays on lymphocyte derived DNA were consistent with <italic toggle="yes">BRCA1</italic> promoter hypermethylation across 10 CpG dinucleotides (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2A</xref>) (average 43% and 41%, respectively) indicating that one allele was fully methylated (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Table 1</xref>, <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 2B, C</xref> and eFigure 1). This hypermethylation pattern was consistent in DNA extracted from buccal mucosa (54% and 69%) and hair follicles (38% and 43%) (eTable 2), representing endoderm and ectoderm derived tissues, respectively. Clonal bisulfite sequencing orthogonally confirmed the <italic toggle="yes">BRCA1</italic> promoter hypermethylation pattern in the two affected women (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figure 2D</xref>).</p><fig id="fig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2 xref-fig-1-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;246934v2/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1:</label><caption hwp:id="caption-1"><p hwp:id="p-24"><bold>A.</bold> Pedigree of family 1. <bold>B.</bold> Pedigree of family 2. Y: years of age tested. uMe: unmethylated <italic toggle="yes">BRCA1</italic> promoter. Me: methylated <italic toggle="yes">BRCA1</italic> promoter. Wt: wild type.</p></caption><graphic xlink:href="246934_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig><fig id="fig2" position="float" orientation="portrait" fig-type="figure" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;246934v2/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2:</label><caption hwp:id="caption-2"><p hwp:id="p-25">Schematic overview of <italic toggle="yes">BRCA1</italic> promoter region (black dots: CpG sites; star: c.-107; green dot: rs799905; arrows: primer locations for clonal bisulfite sequencing; dotted line: pyrosequencing region (A and B). <bold>B and C.</bold> Representative pyrograms (region B) show the level of <italic toggle="yes">BRCA1</italic> promoter methylation in lymphocytes, buccal mucosa and hair derived DNA of an affected and unaffected individual. Five CpGs and a control site (0%) (to ensure complete bisulfite conversion) are shaded and the percentage methylation as a ratio of C:T peak heights is calculated at each site (representing methylated versus unmethylated cytosine). <bold>B.</bold> Affected individual II-4 from Family 1. <bold>C.</bold> Unaffected individual II-1 from Family 1. Further pyogram data (region A) indicating methylation across the <italic toggle="yes">BRCA1</italic> promoter is available in the Supplementary appendix (eFigure 1). <bold>D.</bold> Schematic overview of clonal bisulfite sequencing results allelic discrimination is made based on rs799905 C&gt;G (orange: G; green: C). The novel variant c.-107A&gt;T is present on the methylated allele (yellow: T; blue: A; black is methylated, white is unmethylated).</p></caption><graphic xlink:href="246934_fig2" position="float" orientation="portrait" hwp:id="graphic-2"/></fig><table-wrap id="tbl1" position="float" orientation="portrait" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2 xref-table-wrap-1-3 xref-table-wrap-1-4"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;246934v2/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1:</label><caption hwp:id="caption-3"><p hwp:id="p-26">Summary of <italic toggle="yes">BRCA1</italic> promoter methylation status in lymphocyte derived DNA, clinical phenotype and genotype for the c.-107A&gt;T variant for all tested individuals. M=male, F=female.</p></caption><graphic xlink:href="246934_tbl1" position="float" orientation="portrait" hwp:id="graphic-3"/></table-wrap><p hwp:id="p-27">Segregation analysis for <italic toggle="yes">BRCA1</italic> promoter hypermethylation was undertaken in the two families. In Family 1 the proband’s identical twin (II-5), affected by bilateral grade 3 breast cancer at age 30 and 32 years (no receptor status available) and colorectal cancer at 64 years and II-5’s daughter (III-5), who had been affected by high-grade triple negative breast cancer at 39 years (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-3" hwp:rel-id="F1">Figure 1A</xref>) both had hypermethylation of the <italic toggle="yes">BRCA1</italic> promoter at similar allele frequencies to the proband (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Table 1</xref>, eTable 2). Samples from the parents of the affected twins were not available, both were deceased, and neither had a history of cancer.</p><p hwp:id="p-28">Samples from seven other family members were available (II-1, II-2, II-7, III-1, III-2, III-3 and III-4). Of these, four showed a soma-wide hypermethylated <italic toggle="yes">BRCA1</italic> promoter in blood, buccal mucosa, and hair follicles and in three a normal methylation pattern (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-3" hwp:rel-id="T1">Table 1</xref>, eTable 2, <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Figure 2B, C</xref>, and eFigure 1). In Family 2, the maternal first cousin (III-3) of the proband (III-2) had been diagnosed with high-grade serous ovarian cancer at 48 years, and also had soma-wide hypermethylation of the <italic toggle="yes">BRCA1</italic> promoter. The mother of III-2 was deceased (due to myocardial infarction at 76 years with no history of cancer). Her sister (II-4), the mother of III-3, was alive at 85 years, also with no history of cancer and had similar hypermethylation levels (43%) to her affected daughter and niece. The healthy brother (III-1) of the proband also showed hypermethylation of the <italic toggle="yes">BRCA1</italic> promoter.</p><p hwp:id="p-29">DNA extracted from formalin fixed paraffin embedded breast tumor was available from individual III-5 (Family 1). Genotyping showed loss of the wild type allele across five informative intragenic SNPs (eTable 3) (i.e. only the alleles of the variants not expressed in the cDNA were present), consistent with loss of <italic toggle="yes">BRCA1</italic> as the second hit in the tumor tissue. Expression analysis of <italic toggle="yes">BRCA1</italic> in RNA extracted from lymphocytes was undertaken in individuals with promoter hypermethylation. Absence of heterozygosity across five SNPs with high minor allele frequencies within the <italic toggle="yes">BRCA1</italic> cDNA suggested allelic imbalance (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 3A</xref>), secondary to loss of expression of one allele due to hypermethylation of the <italic toggle="yes">BRCA1</italic> promoter (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figure 3C</xref>).</p><fig id="fig3" position="float" orientation="portrait" fig-type="figure" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;246934v2/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3:</label><caption hwp:id="caption-4"><p hwp:id="p-30"><bold>A.</bold> Representative Sanger sequencing traces demonstrating allelic loss of expression of rs1799917 C&gt;T in exon 11 of <italic toggle="yes">BRCA1</italic>. In the DNA trace, both the C and T nucleotides are present, whereas in the cDNA trace only the C nucleotide is present. <bold>B.</bold> Representative Sanger sequencing traces for novel heterozygous c.-107A&gt;T variant, present in individual with methylated <italic toggle="yes">BRCA1</italic> promoter and absent in an individual with an unmethylated promoter. <bold>C.</bold> Schematic representation of normal pattern of gene expression and transcription (top) and abnormal gene expression and transcription, caused by a germline variant (c.-107), resulting in hypermethylation of the promoter (secondary epimutation) and silencing of one allele.</p></caption><graphic xlink:href="246934_fig3" position="float" orientation="portrait" hwp:id="graphic-4"/></fig><p hwp:id="p-31">Sanger sequencing upstream of the <italic toggle="yes">BRCA1</italic> translation start site identified a novel heterozygous variant c.-107A&gt;T (g.43125358A&gt;T, NM_07294.3) in an affected woman with <italic toggle="yes">BRCA1</italic> promoter hypermethylation in each family (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figure 3B</xref>). This variant segregated with the hypermethylated <italic toggle="yes">BRCA1</italic> allele in all tested individuals in both families and was absent in individuals lacking the hypermethylated allele, confirming that it was in <italic toggle="yes">cis</italic> (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-4" hwp:rel-id="T1">Table 1</xref>, eTable 2). This variant was absent in gnomAD<sup><xref rid="c21" ref-type="bibr" hwp:id="xref-ref-21-2" hwp:rel-id="ref-21">21</xref></sup>, a database that includes whole exome and whole genome sequencing data on 123,136 and 15,496 individuals, respectively. The variant has not been reported in any individual with breast or ovarian cancer in disease-specific databases, including the BRCA Exchange (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://brcaexchange.org" ext-link-type="uri" xlink:href="http://brcaexchange.org" hwp:id="ext-link-3">http://brcaexchange.org</ext-link>).</p><p hwp:id="p-32">The two families (both non-consanguineous white British from North West England) were not knowingly related to each other. All individuals in the two families with promoter hypermethylation and the c.-107A&gt;T variant carried the previously described B1 haplotype (eTable 4, 5)<sup><xref rid="c20" ref-type="bibr" hwp:id="xref-ref-20-2" hwp:rel-id="ref-20">20</xref></sup>. To identify any additional germline variants that may result in promoter hypermethylation, we undertook SNP arrays and whole genome sequencing. SNP array analysis of II-5, III-2, and III-5 (Family 1), and III-2 and III-3 (Family 2) did not identify any other rare or novel copy number variants. Whole genome sequencing analysis was restricted to a candidate region (chr17:42,044,295-44,215,483, <italic toggle="yes">hg38</italic>) 1Mb upstream and downstream of the <italic toggle="yes">BRCA1</italic> gene. Segregation analyses were performed to identify variants in a heterozygous state in the two unrelated affected individuals (III-5, Family 1 and III-2, Family2) and absent in the unaffected individual (II-2, Family 1). This restricted analysis identified 14 variants that were absent from both the gnomAD dataset and dbSNP. Two novel variants (one in intron 2, c.80+661_80+667delAAAAAAA (g. 43123349-43123356delAAAAAAA, NM_007294.3) (eMethods, eFigure 3) and the previously identified c.-107A&gt;T variant) were determined to be within the genomic region for <italic toggle="yes">BRCA1</italic>. Three variants within the candidate interval were present within DNase I hypersensitivity sites characterized across 125 cell types. In combination, these analyses identified c.-107A&gt;T as single novel candidate variant linked to hypermethylation of the promoter (eFigure 2).</p></sec><sec id="s5" hwp:id="sec-18"><title hwp:id="title-19">Discussion</title><p hwp:id="p-33">Here, over 20 years after the initial report that pathogenic variants in <italic toggle="yes">BRCA1</italic> result in familial breast cancer,<sup><xref rid="c22" ref-type="bibr" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref></sup> we demonstrate for the first time transgenerational epigenetic silencing of <italic toggle="yes">BRCA1</italic> in two families with early-onset breast and ovarian cancer. A constitutional epimutation describes an epigenetic change, for example promoter hypermethylation, that results in the transcriptional silencing of a gene that is normally active across a range of normal tissues and predisposes to disease. Sloane <italic toggle="yes">et al</italic>.<sup><xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref></sup> set out four criteria to establish the presence of a constitutional epimutation, which are met in our two families, in that promoter hypermethylation is confined to one allele in normal tissues derived from the mesoderm (blood), hair follicles (ectoderm), and buccal mucosa (endoderm); the level (~50%) and presence of hypermethylation is demonstrated using at least two independent methods (pyrosequencing and clonal bisulfite sequencing); the methylated allele is transcriptionally silent and there is co-segregation of the methylated and transcriptionally silent allele with the phenotype.<sup><xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-2" hwp:rel-id="ref-23">23</xref></sup></p><p hwp:id="p-34">Inherited epigenetic variants have only rarely been described in familial cancer, notably in Lynch syndrome due to hypermethylation of the <italic toggle="yes">MLH1</italic> promoter<sup><xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-2" hwp:rel-id="ref-15">15</xref></sup>, or <italic toggle="yes">MSH2</italic> promoter.<sup><xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-2" hwp:rel-id="ref-16">16</xref></sup> <italic toggle="yes">MLH1</italic> promoter hypermethylation has been reported both in the context of a <italic toggle="yes">cis</italic>-acting germline variant, c.-27C&gt;A (secondary epimutation), and in the absence of any detectable genetic alteration (primary epimutation).<sup><xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref></sup> In contrast <italic toggle="yes">MSH2</italic> promoter hypermethylation has always been associated with a <italic toggle="yes">cis</italic>-acting deletion encompassing the 3’ end of the adjacent <italic toggle="yes">EPCAM</italic> gene.<sup><xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-3" hwp:rel-id="ref-16">16</xref>,<xref rid="c25" ref-type="bibr" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref></sup> Here, we identified a novel <italic toggle="yes">BRCA1</italic> exon 1 variant, c.-107A&gt;T, in <italic toggle="yes">cis</italic> with the hypermethylated promoter, which segregated with the phenotype in both families.</p><p hwp:id="p-35">In this family there is, as yet, no evidence to determine if male to female vertical transmission of the <italic toggle="yes">BRCA1</italic> promoter methylation results in a breast/ovarian cancer phenotype in the next generation. Future predictive testing of the at-risk daughters of male carriers in this family will be able to establish this. However, as there is a linked upstream variant (c.-107A&gt;T), it is likely that transmission will result in promoter methylation and a phenotype.</p><p hwp:id="p-36">The c.-107A&gt;T <italic toggle="yes">BRCA1</italic> variant is found on an ancestral B1 haplotype<sup><xref rid="c20" ref-type="bibr" hwp:id="xref-ref-20-3" hwp:rel-id="ref-20">20</xref></sup> in both families. Although the families are not known to be related to each other, this data indicates that the two families may share a common ancestry. It will be important to determine if this variant occurs in other affected individuals to establish if this variant has arisen more than once and if other non-coding variants can result in <italic toggle="yes">BRCA1</italic> promoter hypermethylation. The c.-107 nucleotide is not highly conserved through mammalian species and <italic toggle="yes">in silico</italic> tools are not informative in predicting its pathogenicity. Notably exon one is not normally sequenced in clinical <italic toggle="yes">BRCA1</italic> testing and so the c.-107A&gt;T variant would not have been detected by routine testing. Even if it had been identified by sequence analysis, without the methylation studies it would be classified as a variant of unknown significance. Therefore, promoter methylation studies are merited to clarify the functional effect of all rare or novel 5’ variants in <italic toggle="yes">BRCA1</italic>. The specific mechanism by which the 5’ variant results in promoter hypermethylation is, as yet, unknown.</p><p hwp:id="p-37">Importantly, the clinical presentation of the affected individuals in the two families is consistent with the phenotype in other families with <italic toggle="yes">BRCA1</italic> pathogenic variants and does not indicate any specific clinical features that would prioritize individuals with familial breast/ovarian cancer without coding <italic toggle="yes">BRCA1</italic> pathogenic variants for methylation analysis. Although based on only two families the penetrance of the hypermethylated <italic toggle="yes">BRCA1</italic> promoter is 71·4% in informative women. This is consistent with estimates of cumulative risks by age 80 years for females with pathogenic <italic toggle="yes">BRCA1</italic> variants of 75% for breast cancer.<sup><xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-2" hwp:rel-id="ref-5">5</xref></sup> The two unaffected female variant carriers were born before 1940 when penetrance for <italic toggle="yes">BRCA1</italic> pathogenic variants was much lower.<sup><xref rid="c26" ref-type="bibr" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">26</xref></sup> For the male relatives, as expected, there is no evidence of an elevated cancer risk.<sup><xref rid="c27" ref-type="bibr" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref></sup> Variable (mosaic) levels of <italic toggle="yes">BRCA1</italic> promoter methylation are detected in normal somatic tissues from individuals carrying the 5’ variant ranging from 24% in hair in individual II-5 in Family 1 to 69% in buccal mucosa in individual III-2 in Family 2, both women have bilateral breast cancer. There is no correlation between these promoter methylation levels and the clinical phenotype, for example the variant carriers (II-4) in Family 2 has methylation levels &gt;40% but does not have cancer at 85 years. We detected the epimutation in two of 49 families ascertained in North West England with a Manchester score of &gt;34. This equates to this mechanism accounting for at least 1.25% of <italic toggle="yes">BRCA1</italic> pathogenic variants in our very high-risk familial breast/ovary cohort and increases sensitivity from 71·8% to at least 72·7% in families with a high likelihood of a <italic toggle="yes">BRCA1/2</italic> pathogenic variant. Therefore, this mechanism is more common in our population than deep intronic mutations.<sup><xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-5" hwp:rel-id="ref-7">7</xref></sup> Further, in our familial breast/ovarian cancer cohort, next generation sequencing of a panel of genes associated with an increased risk of breast cancer increased the diagnostic yield for familial breast cancer by a similar amount, but only revealed variants in genes (<italic toggle="yes">ATM/CHEK2</italic>) with less clear actionability.<sup><xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-3" hwp:rel-id="ref-5">5</xref>,<xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-6" hwp:rel-id="ref-7">7</xref></sup> The uplift achieved by methylation testing would argue that <italic toggle="yes">BRCA1</italic> promoter methylation testing is a valuable adjunct to sequence and copy number analysis for individuals with a strong family history of breast and/or ovarian cancer.</p><p hwp:id="p-38">In summary, we identified two families with transgenerational allele specific promoter methylation of <italic toggle="yes">BRCA1</italic>, which is present in all three germ layers, resulting in transcriptional silencing of one allele. The promoter hypermethylation is linked to an <italic toggle="yes">in cis</italic> variant c.-107T&gt;A. This novel mechanism may explain some of the missing heritability in familial breast/ovarian cancer families.</p></sec></body><back><ack hwp:id="ack-1"><title hwp:id="title-20">Acknowledgements</title><p hwp:id="p-39">Many thanks to the family members for their participation and co-operation. Funded by Prevent Breast Cancer (GA 12-006 and GA 15-002) and the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007). DGE is an NIHR Senior Investigator (NF-SI-0513-10076). JE is funded by a Post Doctoral Research Fellowship from Health Education England Genomics Education Programme. The views expressed in this publication are those of the author(s) and not necessarily those of HEE GEP. All funding bodies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p hwp:id="p-40">DGE and EvV had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All tested individuals gave consent to present their personal information in this manuscript.</p><p hwp:id="p-41">With thanks to Jeanette Rothwell for sample collection and Natasha Leo for technical assistance. The authors would like to thank the Genome Aggregation Database (gnomAD) and the groups that provided exome and genome variant data to this resource. A full list of contributing groups can be found at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://gnomad.broadinstitute.org/about" ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org/about" hwp:id="ext-link-4">http://gnomad.broadinstitute.org/about</ext-link>.</p><p hwp:id="p-42">TA declares an honorarium from Illumina for speaking. The other authors have no disclosures or conflicts of interest to declare. DGE, EvV, MS, and WN designed the study. DGE and WN obtained funding. DGE, DE, and FL ascertained patients and collated all relevant clinical information. EvV, MS, HB, AW, GB, JE, TA, and JSL carried out the experiments. All authors contributed to the analysis of the data. DGE, EvV, MS, and WN drafted the manuscript. All authors commented and approved the final version.</p></ack><ref-list hwp:id="ref-list-1"><title hwp:id="title-21">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Siegel R"><surname>Siegel</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Naishadham D"><surname>Naishadham</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jemal A."><surname>Jemal</surname> <given-names>A.</given-names></string-name> <article-title hwp:id="article-title-2">Cancer statistics, 2013</article-title>. <source hwp:id="source-1">CA Cancer J Clin</source> <year>2013</year>; <volume>63</volume>(<issue>1</issue>): <fpage>11</fpage>–<lpage>30</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><article-title hwp:id="article-title-3">Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group</article-title>. <source hwp:id="source-2">British journal of cancer</source> <year>2000</year>; <volume>83</volume>(<issue>10</issue>): <fpage>1301</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Alsop K"><surname>Alsop</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fereday S"><surname>Fereday</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Meldrum C"><surname>Meldrum</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-4">BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group</article-title>. <source hwp:id="source-3">Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source> <year>2012</year>; <volume>30</volume>(<issue>21</issue>): <fpage>2654</fpage>–<lpage>63</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Eccles SA"><surname>Eccles</surname> <given-names>SA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Aboagye EO"><surname>Aboagye</surname> <given-names>EO</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ali S"><surname>Ali</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-5">Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer</article-title>. <source hwp:id="source-4">Breast cancer research: BCR</source> <year>2013</year>; <volume>15</volume>(<issue>5</issue>): <fpage>R92</fpage>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1 xref-ref-5-2 xref-ref-5-3"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Easton DF"><surname>Easton</surname> <given-names>DF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pharoah PD"><surname>Pharoah</surname> <given-names>PD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Antoniou AC"><surname>Antoniou</surname> <given-names>AC</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-6">Gene-panel sequencing and the prediction of breast-cancer risk</article-title>. <source hwp:id="source-5">The New England journal of medicine</source> <year>2015</year>; <volume>372</volume>(<issue>23</issue>): <fpage>2243</fpage>–<lpage>57</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Palma MD"><surname>Palma</surname> <given-names>MD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Domchek SM"><surname>Domchek</surname> <given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stopfer J"><surname>Stopfer</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-7">The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families</article-title>. <source hwp:id="source-6">Cancer research</source> <year>2008</year>; <volume>68</volume>(<issue>17</issue>): <fpage>7006</fpage>–<lpage>14</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1 xref-ref-7-2 xref-ref-7-3 xref-ref-7-4 xref-ref-7-5 xref-ref-7-6"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Byers H"><surname>Byers</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wallis Y"><surname>Wallis</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="van Veen EM"><surname>van Veen</surname> <given-names>EM</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-8">Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing</article-title>. <source hwp:id="source-7">Eur J Hum Genet</source> <year>2016</year>; <volume>24</volume>(<issue>11</issue>): <fpage>1591</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Tutt A"><surname>Tutt</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Robson M"><surname>Robson</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Garber JE"><surname>Garber</surname> <given-names>JE</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-9">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial</article-title>. <source hwp:id="source-8">Lancet</source> <year>2010</year>; <volume>376</volume>(<issue>9737</issue>): <fpage>235</fpage>–<lpage>44</lpage>.</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1 xref-ref-9-2"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Herman JG"><surname>Herman</surname> <given-names>JG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Baylin SB"><surname>Baylin</surname> <given-names>SB</given-names></string-name>. <article-title hwp:id="article-title-10">Gene silencing in cancer in association with promoter hypermethylation</article-title>. <source hwp:id="source-9">The New England journal of medicine</source> <year>2003</year>; <volume>349</volume>(<issue>21</issue>): <fpage>2042</fpage>–<lpage>54</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Rice JC"><surname>Rice</surname> <given-names>JC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Massey-Brown KS"><surname>Massey-Brown</surname> <given-names>KS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Futscher BW."><surname>Futscher</surname> <given-names>BW.</given-names></string-name> <article-title hwp:id="article-title-11">Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells</article-title>. <source hwp:id="source-10">Oncogene</source> <year>1998</year>; <volume>17</volume>(<issue>14</issue>): <fpage>1807</fpage>–<lpage>12</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Esteller M"><surname>Esteller</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Silva JM"><surname>Silva</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dominguez G"><surname>Dominguez</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-12">Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors</article-title>. <source hwp:id="source-11">Journal of the National Cancer Institute</source> <year>2000</year>; <volume>92</volume>(<issue>7</issue>): <fpage>564</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Tapia T"><surname>Tapia</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Smalley SV"><surname>Smalley</surname> <given-names>SV</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kohen P"><surname>Kohen</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-13">Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors</article-title>. <source hwp:id="source-12">Epigenetics</source> <year>2008</year>; <volume>3</volume>(<issue>3</issue>): <fpage>157</fpage>–<lpage>63</lpage>.</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Yamashita N"><surname>Yamashita</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tokunaga E"><surname>Tokunaga</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kitao H"><surname>Kitao</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-14">Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer</article-title>. <source hwp:id="source-13">Clinical breast cancer</source> <year>2015</year>; <volume>15</volume>(<issue>6</issue>): <fpage>498</fpage>–<lpage>504</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Hansmann T"><surname>Hansmann</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pliushch G"><surname>Pliushch</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Leubner M"><surname>Leubner</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-15">Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer</article-title>. <source hwp:id="source-14">Human molecular genetics</source> <year>2012</year>; <volume>21</volume>(<issue>21</issue>): <fpage>4669</fpage>–<lpage>79</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1 xref-ref-15-2"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Hitchins MP"><surname>Hitchins</surname> <given-names>MP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wong JJ"><surname>Wong</surname> <given-names>JJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Suthers G"><surname>Suthers</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-16">Inheritance of a cancer-associated MLH1 germ-line epimutation</article-title>. <source hwp:id="source-15">The New England journal of medicine</source> <year>2007</year>; <volume>356</volume>(<issue>7</issue>): <fpage>697</fpage>–<lpage>705</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1 xref-ref-16-2 xref-ref-16-3"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Ligtenberg MJ"><surname>Ligtenberg</surname> <given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kuiper RP"><surname>Kuiper</surname> <given-names>RP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chan TL"><surname>Chan</surname> <given-names>TL</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-17">Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1</article-title>. <source hwp:id="source-16">Nature genetics</source> <year>2009</year>; <volume>41</volume>(<issue>1</issue>): <fpage>112</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Stefansson OA"><surname>Stefansson</surname> <given-names>OA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Villanueva A"><surname>Villanueva</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vidal A"><surname>Vidal</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Marti L"><surname>Marti</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Esteller M."><surname>Esteller</surname> <given-names>M.</given-names></string-name> <article-title hwp:id="article-title-18">BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer</article-title>. <source hwp:id="source-17">Epigenetics</source> <year>2012</year>; <volume>7</volume>(<issue>11</issue>): <fpage>1225</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1 xref-ref-18-2"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Evans DG"><surname>Evans</surname> <given-names>DG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Eccles DM"><surname>Eccles</surname> <given-names>DM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rahman N"><surname>Rahman</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-19">A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO</article-title>. <source hwp:id="source-18">J Med Genet</source> <year>2004</year>; <volume>41</volume>(<issue>6</issue>): <fpage>474</fpage>–<lpage>80</lpage>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1 xref-ref-19-2"><label>19.</label><citation publication-type="other" citation-type="journal" ref:id="246934v2.19" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Evans DG"><surname>Evans</surname> <given-names>DG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Harkness EF"><surname>Harkness</surname> <given-names>EF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Plaskocinska I"><surname>Plaskocinska</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-20">Pathology update to the Manchester Scoring System based on testing in over 4000 families</article-title>. <source hwp:id="source-19">J Med Genet</source> <year>2017</year> May 12 (Epub ahead of print).</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1 xref-ref-20-2 xref-ref-20-3"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Frosk P"><surname>Frosk</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Burgess S"><surname>Burgess</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dyck T"><surname>Dyck</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jobse R"><surname>Jobse</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spriggs EL"><surname>Spriggs</surname> <given-names>EL</given-names></string-name>. <article-title hwp:id="article-title-21">The use of ancestral haplotypes in the molecular diagnosis of familial breast cancer</article-title>. <source hwp:id="source-20">Genetic testing</source> <year>2007</year>; <volume>11</volume>(<issue>3</issue>): <fpage>208</fpage>–<lpage>15</lpage>.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1 xref-ref-21-2"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Lek M"><surname>Lek</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Karczewski KJ"><surname>Karczewski</surname> <given-names>KJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Minikel EV"><surname>Minikel</surname> <given-names>EV</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-22">Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source hwp:id="source-21">Nature</source> <year>2016</year>; <volume>536</volume>(<issue>7616</issue>): <fpage>285</fpage>–<lpage>91</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Miki Y"><surname>Miki</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Swensen J"><surname>Swensen</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shattuck-Eidens D"><surname>Shattuck-Eidens</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-23">A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1</article-title>. <source hwp:id="source-22">Science</source> <year>1994</year>; <volume>266</volume>(<issue>5182</issue>): <fpage>66</fpage>–<lpage>71</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1 xref-ref-23-2"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Sloane MA"><surname>Sloane</surname> <given-names>MA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ward RL"><surname>Ward</surname> <given-names>RL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hesson LB"><surname>Hesson</surname> <given-names>LB</given-names></string-name>. <article-title hwp:id="article-title-24">Defining the criteria for identifying constitutional epimutations</article-title>. <source hwp:id="source-23">Clinical epigenetics</source> <year>2016</year>; <volume>8</volume>: <fpage>39</fpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1"><label>24.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Hitchins MP"><surname>Hitchins</surname> <given-names>MP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rapkins RW"><surname>Rapkins</surname> <given-names>RW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kwok CT"><surname>Kwok</surname> <given-names>CT</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-25">Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5’UTR</article-title>. <source hwp:id="source-24">Cancer cell</source> <year>2011</year>; <volume>20</volume>(<issue>2</issue>): <fpage>200</fpage>–<lpage>13</lpage>.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Hitchins MP"><surname>Hitchins</surname> <given-names>MP</given-names></string-name>. <article-title hwp:id="article-title-26">Constitutional epimutation as a mechanism for cancer causality and heritability?</article-title> <source hwp:id="source-25">Nature reviews Cancer</source> <year>2015</year>; <volume>15</volume>(<issue>10</issue>): <fpage>625</fpage>–<lpage>34</lpage>.</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Evans DG"><surname>Evans</surname> <given-names>DG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shenton A"><surname>Shenton</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Woodward E"><surname>Woodward</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lalloo F"><surname>Lalloo</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Howell A"><surname>Howell</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Maher ER."><surname>Maher</surname> <given-names>ER.</given-names></string-name> <article-title hwp:id="article-title-27">Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family</article-title>. <source hwp:id="source-26">BMC cancer</source> <year>2008</year>; <volume>8</volume>: <fpage>155</fpage>.</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="246934v2.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Moran A"><surname>Moran</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="O’Hara C"><surname>O’Hara</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Khan S"><surname>Khan</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-28">Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations</article-title>. <source hwp:id="source-27">Familial cancer</source> <year>2012</year>; <volume>11</volume>(<issue>2</issue>): <fpage>235</fpage>–<lpage>42</lpage>.</citation></ref></ref-list></back></article>
